BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Post by peteswimon Apr 05, 2011 11:13am

267 Views

Post# 18386930

Bids building

Nice support

# Orders	Shares	Bid	Ask	Shares	# Orders
18	1004500	0.105	0.110	213500	6
30	973500	0.100	0.115	408000	13
5	333000	0.095	0.120	613500	17
4	215000	0.090	0.125	489500	14
1	30000	0.085	0.130	284000	13